Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21waf1

Experimental Cell Research

Volumn 298, Issue 2, 2004, Pages 560-573

  Chopin, V ^a   Slomianny, C ^b   Hondermarck, H ^a   Le Bourhis, X ^a  

^a UNIV LILLE   (France)

^b Université des Sciences et Technologies de Lille   (France)

Author keywords

Apoptosis; Breast cancer; Butyrate; CDK; cyclin dependent kinase; Death receptors; FADD; Fas; Fas L; Fas ligand; Fas associated death domain; FCS; fetal calf serum; HDAC; histone deacetylase; NaB; P21waf1; PCNA; sodium butyrate; TNF alpha; TRAIL

Indexed keywords

BUTYRIC ACID; CELL NUCLEUS ANTIGEN; DEATH RECEPTOR 5; PROTEIN BID; PROTEIN P21; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; GENE MUTATION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION;

MINK CELL FOCUS-FORMING VIRUS;

EID: 3242725832     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2004.04.038     Document Type: Article

References (71)

1. Kim D.H., Kim M., Kwon H.J. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J. Biochem. Mol. Biol. 36:2003;110-119
2. Pellizzaro C., Coradini D., Daniotti A., Abolafio G., Daidone M.G. Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines. Int. J. Cancer. 91:2001;654-657
3. Gillenwater A., Zou C.P., Zhong M., Lotan R. Effects of sodium butyrate on growth, differentiation, and apoptosis in head and neck squamous carcinoma cell lines. Head Neck. 22:2000;247-256
4. Bernhard D., Ausserlechner M.J., Tonko M., Loffler M., Hartmann B.L., Csordas A., Kofler R. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J. 13:1999;1991-2001
5. Joensuu T., Mester J. Inhibition of cell cycle progression by sodium butyrate in normal rat kidney fibroblasts is altered by expression of the adenovirus 5 early 1A gene. Biosci. Rep. 14:1994;291-300
6. Witt O., Schulze S., Kanbach K., Roth C., Pekrun A. Tumor cell differentiation by butyrate and environmental stress. Cancer Lett. 171:2001;173-182
7. Reynolds S., Rajagopal S., Chakrabarty S. Differentiation-inducing effect of retinoic acid, difluoromethylornithine, sodium butyrate and sodium suramin in human colon cancer cells. Cancer Lett. 134:1998;53-60
8. Domenica Cappellini M., Graziadei G., Ciceri L., Comino A., Bianchi P., Porcella A., Fiorelli G. Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study. Blood Cells Mol. Diseases. 26:2000;105-111
9. Patnaik A., Rowinsky E.K., Villalona M.A., Hammond L.A., Britten C.D., Siu L.L., Goetz A., Felton S.A., Burton S., Valone F.H., Eckhardt S.G. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. 8:2002;2142-2148
10. Gore S.D., Weng L.J., Figg W.D., Zhai S., Donehower R.C., Dover G., Grever M.R., Griffin C., Grochow L.B., Hawkins A., Burks K., Zabelena Y., Miller C.B. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 8:2002;963-970
11. Edelman M.J., Bauer K., Khanwani S., Tait N., Trepel J., Karp J., Nemieboka N., Chung E.J., Van Echo D. Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Cancer Chemother. Pharmacol. 51:2003;439-444
12. Davie J.R. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 133:2003;2485S-2493S
13. Kamitani H., Taniura S., Watanabe K., Sakamoto M., Watanabe T., Eling T. Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced. Neuro-Oncology. 4:2002;95-101
14. Tan S., Seow T.K., Liang R.C., Koh S., Lee C.P., Chung M.C., Hooi S.C. Proteome analysis of butyrate-treated human colon cancer cells (HT-29). Int. J. Cancer. 98:2002;523-531
15. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 282:1998;1497-1501
16. Brugarolas J., Moberg K., Boyd S.D., Taya Y., Jacks T., Lees J.A. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc. Natl. Acad. Sci. U.S.A. 96:1999;1002-1007
17. Chang B.D., Watanabe K., Broude E.V., Fang J., Poole J.C., Kalinichenko T.V., Roninson I.B. Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc. Natl. Acad. Sci. U.S.A. 97:2000;4291-4296
18. Hengst L., Gopfert U., Lashuel H.A., Reed S.I. Complete inhibition of Cdk/cyclin by one molecule of p21(Cip1). Genes Dev. 12:1998;3882-3888
19. Suzuki A., Kawano H., Hayashida M., Hayasaki Y., Tsutomi Y., Akahane K. Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ. 7:2000;721-728
20. Qiao L., McKinstry R., Gupta S., Gilfor D., Windle J.J., Hylemon P.B., Grant S., Fisher P.B., Dent P. Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53. Hepatology. 36:2002;39-48
21. Yang H.L., Pan J.X., Sun L., Yeung S.C. p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells. J. Clin. Endocrinol. Metab. 88:2003;763-772
22. French L.E., Tschopp J. Protein-based therapeutic approaches targeting death receptors. Cell Death Differ. 10:2003;117-123
23. Toillon R.A., Descamps S., Adriaenssens E., Ricort J.M., Bernard D., Boilly B., Le Bourhis X. Normal breast epithelial cells induce apoptosis of breast cancer cells via Fas signaling. Exp. Cell Res. 275:2002;31-43
24. Ozoren N., El-Deiry W.S. Cell surface Death Receptor signaling in normal and cancer cells. Semin. Cancer Biol. 13:2003;135-147
25. Nagane M., Huang H.J., Cavenee W.K. The potential of TRAIL for cancer chemotherapy. Apoptosis. 6:2001;191-197
26. Inoue H., Shiraki K., Ohmori S., Sakai T., Deguchi M., Yamanaka T., Okano H., Nakano T. Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Int. J. Mol. Med. 9:2002;521-525
27. Evdokiou A., Bouralexis S., Atkins G.J., Chai F., Hay S., Clayer M., Findlay D.M. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int. J. Cancer. 99:2002;491-504
28. Rahmani M., Dai Y., Grant S. The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process. Exp. Cell Res. 277:2002;31-47
29. Kovarikova M., Pachernik J., Hofmanova J., Zadak Z., Kozubik A. TNF-alpha modulates the differentiation induced by butyrate in the HT-29 human colon adenocarcinoma cell line. Eur. J. Cancer. 36:2000;1844-1852
30. Hernandez A., Thomas R., Smith F., Sandberg J., Kim S., Chung D.H., Evers B.M. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery. 130:2001;265-272
31. Bonnotte B., Favre N., Reveneau S., Micheau O., Droin N., Garrido C., Fontana A., Chauffert B., Solary E., Martin F. Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate. Cell Death Differ. 5:1998;480-487
32. Chopin V., Toillon R.A., Jouy N., Le Bourhis X. Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells. Br. J. Pharmacol. 135:2002;79-86
33. Sartorius U., Schmitz I., Krammer P.H. Molecular mechanisms of death-receptor-mediated apoptosis. ChemBioChem. 2:2001;20-29
34. Milner A.E., Palmer D.H., Hodgkin E.A., Eliopoulos A.G., Knox P.G., Poole C.J., Kerr D.J., Young L.S. Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells. Cell Death Differ. 9:2002;287-300
35. Werner A.B., de Vries E., Tait S.W., Bontjer I., Borst J. TRAIL receptor and CD95 signal to mitochondria via FADD, caspase-8/10, Bid, and Bax but differentially regulate events downstream from truncated Bid. J. Biol. Chem. 277:2002;40760-40767
36. Ruiz-Ruiz C., Lopez-Rivas A. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. Biochem. J. 365:2002;825-832
37. Slee E.A., Harte M.T., Kluck R.M., Wolf B.B., Casiano C.A., Newmeyer D.D., Wang H.G., Reed J.C., Nicholson D.W., Alnemri E.S., Green D.R., Martin S.J. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol. 144:1999;281-292
38. Siavoshian S., Blottiere H.M., Cherbut C., Galmiche J.P. Butyrate stimulates cyclin D and p21 and inhibits cyclin-dependent kinase 2 expression in HT-29 colonic epithelial cells. Biochem. Biophys. Res. Commun. 232:1997;169-172
39. Sawa H., Murakami H., Ohshima Y., Sugino T., Nakajyo T., Kisanuki T., Tamura Y., Satone A., Ide W., Hashimoto I., Kamada H. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol. 18:2001;109-114
40. Greenberg V.L., Williams J.M., Boghaert E., Mendenhall M., Ain K.B., Zimmer S.G. Butyrate alters the expression and activity of cell cycle components in anaplastic thyroid carcinoma cells. Thyroid. 11:2001;21-29
41. Ito N., Sawa H., Nagane M., Noguchi A., Hara M., Saito I. Inhibitory effects of sodium butyrate on proliferation and invasiveness of human glioma cells. Neurosurgery. 49:2001;430-436. (discussion 436-7)
42. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104:1999;155-162
43. Egeblad M., Jaattela M. Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells. Int. J. Cancer. 86:2000;617-625
44. Nagane M., Pan G., Weddle J.J., Dixit V.M., Cavenee W.K., Huang H.J. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60:2000;847-853
45. Nimmanapalli R., Perkins C.L., Orlando M., O'Bryan E., Nguyen D., Bhalla K.N. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 61:2001;759-763
46. Wu X.X., Kakehi Y., Mizutani Y., Nishiyama H., Kamoto T., Megumi Y., Ito N., Ogawa O. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int. J. Cancer. 104:2003;409-417
47. Friesen C., Fulda S., Debatin K.M. Cytotoxic drugs and the CD95 pathway. Leukemia. 13:1999;1854-1858
48. Ruemmele F.M., Schwartz S., Seidman E.G., Dionne S., Levy E., Lentze M.J. Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway. Gut. 52:2003;94-100
49. Giuliano M., Lauricella M., Calvaruso G., Carabillo M., Emanuele S., Vento R., Tesoriere G. The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res. 59:1999;5586-5595
50. Giardina C., Boulares H., Inan M.S. NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species. Biochim. Biophys. Acta. 1448:1999;425-438
51. Chopin V., Toillon R.A., Jouy N., Le Bourhis X. P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene. 23:2004;21-29
52. Hara I., Miyake H., Hara S., Arakawa S., Kamidono S. Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity. Int. J. Oncol. 17:2000;1213-1218
53. Asada M., Yamada T., Ichijo H., Delia D., Miyazono K., Fukumuro K., Mizutani S. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 18:1999;1223-1234
54. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 13:2003;65-70
55. Peschiaroli A., Figliola R., Coltella L., Strom A., Valentini A., D'Agnano I., Maione R. MyoD induces apoptosis in the absence of RB function through a p21(WAF1)-dependent re-localization of cyclin/cdk complexes to the nucleus. Oncogene. 21:2002;8114-8127
56. Rosato R.R., Almenara J.A., Dai Y., Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2:2003;1273-1284
57. Scott M., Bonnefin P., Vieyra D., Boisvert F.M., Young D., Bazett-Jones D.P., Riabowol K. UV-induced binding of ING1 to PCNA regulates the induction of apoptosis. J. Cell. Sci. 114:2001;3455-3462
58. Kitaura H., Shinshi M., Uchikoshi Y., Ono T., Iguchi-Ariga S.M., Ariga H. Reciprocal regulation via protein-protein interaction between c-Myc and p21(cip1/waf1/sdi1) in DNA replication and transcription. J. Biol. Chem. 275:2000;10477-10483
59. Funk J.O., Waga S., Harry J.B., Espling E., Stillman B., Galloway D.A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 11:1997;2090-2100
60. Feng X., Hara Y., Riabowol K. Different HATS of the ING1 gene family. Trends Cell Biol. 12:2002;532-538
61. Satou M., Aizawa S., Hayakari M., Ookawa K., Tsuchida S. Enhanced sensitivity to cis-diamminedichloro-platinum(II) of a human carcinoma cell line with mutated p53 gene by cyclin-dependent kinase inhibitor p21(WAF1) expression. Cancer Sci. 94:2003;286-291
62. Qin L.F., Ng I.O. Exogenous expression of p21(WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer Lett. 172:2001;7-15
63. Lincet H., Poulain L., Remy J.S., Deslandes E., Duigou F., Gauduchon P., Staedel C. The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett. 161:2000;17-26
64. Han Z., Wei W., Dunaway S., Darnowski J.W., Calabresi P., Sedivy J., Hendrickson E.A., Balan K.V., Pantazis P., Wyche J.H. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem. 277:2002;17154-17160
65. Mahyar-Roemer M., Roemer K. p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene. 20:2001;3387-3398
66. Kokunai T., Urui S., Tomita H., Tamaki N. Overcoming of radioresistance in human gliomas by p21WAF1/CIP1 antisense oligonucleotide. J. Neuro-Oncol. 51:2001;111-119
67. Burgess A.J., Pavey S., Warrener R., Hunter L.J., Piva T.J., Musgrove E.A., Saunders N., Parsons P.G., Gabrielli B.G. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol. 60:2001;828-837
68. Xu S.Q., El-Deiry W.S. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem. Biophys. Res. Commun. 269:2000;179-190
69. Held J., Schulze-Osthoff K. Potential and caveats of TRAIL in cancer therapy. Drug Resist. Updat. 4:2001;243-252
70. Muzio M., Chinnaiyan A.M., Kischkel F.C., O'Rourke K., Shevchenko A., Ni J., Scaffidi C., Bretz J.D., Zhang M., Gentz R., Mann M., Krammer P.H., Peter M.E., Dixit V.M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 85:1996;817-827
71. Wallach D., Boldin M., Goncharov T., Goltsev Y., Mett I., Malinin N., Adar R., Kovalenko A., Varfolomeev E. Exploring cell death mechanisms by analyzing signaling cascades of the TNF/NGF receptor family. Behring Inst. Mitt. 1996;144-155